Evidence from systematic reviews of randomized trials on enteral lactoferrin supplementation in preterm neonates.
Evidence from systematic reviews of randomized trials on enteral lactoferrin supplementation in preterm neonates.
复制标题
来自早产儿肠内补充乳铁蛋白随机试验的系统评价的证据。
DOI：
10.1139/bcb-2020-0136
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Tarnow-Mordi,WilliamO
中科院分区：
文献类型：
--
作者：
Pammi,Mohan;Preidis,GeoffreyA;Tarnow-Mordi,WilliamO
在这篇评论中，我们总结了关于早产儿肠内补充乳铁蛋白的随机对照试验的最新证据。我们最近完成的系统性综述包括在世界各地进行的12项随机对照试验。我们的荟萃分析表明，在减少迟发性脓毒症、迟发性真菌败血症、住院时间和尿路感染方面有临床益处。没有任何不良反应。在补充乳铁蛋白的早产儿中，坏死性小肠结肠炎、死亡率或神经发育障碍的发生率没有统计学上的显著下降。在大型和小型研究中，乳铁蛋白对迟发性败血症的影响有显著的统计学异质性，这可能反映了小的研究偏见，补充乳铁蛋白产品的有效性、剂量或持续时间的差异，或者潜在的人群风险的差异，或者任何或所有这些。
In this commentary, we summarize the current evidence from randomized controlled trials on enteral lactoferrin supplementation in preterm neonates. Our recently completed systematic review includes 12 randomized controlled trials performed all over the world. Our meta-analysis suggests clinical benefit in decreasing late-onset sepsis, late-onset fungal sepsis, length of stay in the hospital and urinary tract infections. There were no adverse effects. There was no statistically significant decrease in necrotizing enterocolitis, mortality or neurodevelopmental impairment in lactoferrin supplemented preterm infants. There was significant statistical heterogeneity in the effects of lactoferrin on late-onset sepsis between larger and smaller studies, which may reflect either small study biases, differences in the effectiveness, dose or duration of supplemental lactoferrin products, or differences in underlying population risk, or any or all of these.